JPMorgan Chase & Co. Cuts Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

JPMorgan Chase & Co. lowered its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 4.9% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 261,934 shares of the company’s stock after selling 13,509 shares during the period. JPMorgan Chase & Co.’s holdings in Voyager Therapeutics were worth $1,532,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Erste Asset Management GmbH purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $6,192,000. Armistice Capital LLC boosted its stake in shares of Voyager Therapeutics by 11.3% during the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares during the period. Barclays PLC boosted its stake in shares of Voyager Therapeutics by 55.8% during the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock valued at $612,000 after purchasing an additional 37,398 shares during the period. Verition Fund Management LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter valued at approximately $216,000. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Voyager Therapeutics by 19.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 171,856 shares of the company’s stock valued at $1,005,000 after purchasing an additional 28,333 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VYGR. Cantor Fitzgerald initiated coverage on Voyager Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $5.73 price objective for the company. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Wedbush initiated coverage on Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 target price for the company. Finally, Citigroup initiated coverage on Voyager Therapeutics in a report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price for the company. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and a consensus price target of $15.97.

Voyager Therapeutics Stock Performance

Shares of NASDAQ:VYGR opened at $5.53 on Friday. The stock’s 50-day simple moving average is $5.82 and its two-hundred day simple moving average is $6.67. Voyager Therapeutics, Inc. has a 52-week low of $4.99 and a 52-week high of $10.66. The stock has a market capitalization of $302.10 million, a price-to-earnings ratio of 7.79 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The company had revenue of $24.63 million for the quarter, compared to the consensus estimate of $12.63 million. During the same quarter last year, the company earned ($0.59) EPS. As a group, equities analysts forecast that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Transactions at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the business’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. The trade was a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 10,778 shares of company stock worth $58,548. 4.53% of the stock is currently owned by company insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.